Some more from the article;
'But Bioshares' David Blake notes Prima's enrolments for a 1000-patient phase-three trial (for patients with epithelial ovarian cancer) have been sluggish.
Enrolments opened in February and the process was to take two years, but only 16 had been signed up by last month. "The longer the phase-three trial takes to complete then the greater the impact on Prima's working capital requirements," he cautions.'
Which is exactly what I wrote a couple of weeks ago and was drawn and quartered for it.
that has shaken the tree, page-38
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 31.8¢ | $845.3K | 2.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 140318 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 14222 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |